RNA (Atrium Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by RNA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-22 | Brendan R. Winslow | Chief Financial Officer | A | — | — |
| 2026-04-22 | Husam Younis | Chief Scientific Officer | A | — | — |
| 2026-04-22 | Rocio Martin Hoyos | Chief Strategy Officer | A | — | — |
| 2026-04-22 | Stephanie Kenney | See Remarks | A | — | — |
| 2026-04-22 | Steven George Hughes | Chief Medical Officer | A | — | — |
| 2026-04-22 | Kathleen P. Gallagher | See Remarks | A | — | — |
| 2026-01-23 | Steven George Hughes | Chief Medical Officer | Sell | — | — |
| 2026-01-23 | Teresa McCarthy | Chief Human Resources Officer | Sell | — | — |
| 2026-01-23 | W. Michael Flanagan | Chief Scientific Officer | Sell | — | — |
| 2026-01-23 | Michael F MacLean | Chief Financial Officer | Sell | — | — |
| 2026-01-23 | ARTHUR A LEVIN | Director | Sell | — | — |
| 2026-01-23 | Sarah Boyce | President and CEO | Sell | — | — |
| 2026-01-09 | Charles Calderaro III | Chief Technical Officer | Sell | — | — |
| 2026-01-09 | Michael F MacLean | Chief Financial Officer | Sell | — | — |
| 2026-01-09 | Steven George Hughes | Chief Medical Officer | Sell | — | — |
| 2026-01-09 | Teresa McCarthy | Chief Human Resources Officer | Sell | — | — |
| 2026-01-09 | W. Michael Flanagan | Chief Scientific Officer | Sell | — | — |
| 2026-01-09 | John B Moriarty | Chief Legal Officer | Sell | — | — |
| 2026-01-09 | Sarah Boyce | President and CEO | Sell | — | — |
| 2025-12-22 | ARTHUR A LEVIN | Director | G | — | — |
| 2025-12-19 | Charles Calderaro III | Chief Technical Officer | MIXED | — | — |
| 2025-12-19 | John B Moriarty | Chief Legal Officer | MIXED | — | — |
| 2025-12-19 | Eric Mosbrooker | Chief Commercial Officer | MIXED | — | — |
| 2025-12-19 | W. Michael Flanagan | Chief Scientific Officer | MIXED | — | — |
| 2025-12-19 | Kathleen P. Gallagher | Chief Program Officer | MIXED | — | — |
| 2025-12-19 | Teresa McCarthy | Chief Human Resources Officer | MIXED | — | — |
| 2025-12-19 | Sarah Boyce | President and CEO | MIXED | — | — |
| 2025-10-24 | Steven George Hughes | Chief Medical Officer | MIXED | — | — |
| 2025-10-17 | Teresa McCarthy | Chief Human Resources Officer | MIXED | — | — |
| 2025-10-07 | Eric Mosbrooker | Chief Commercial Officer | MIXED | — | — |
| 2025-09-23 | Steven George Hughes | Chief Medical Officer | MIXED | — | — |
| 2025-09-17 | Steven George Hughes | Chief Medical Officer | MIXED | — | — |
| 2025-09-17 | Teresa McCarthy | Chief Human Resources Officer | MIXED | — | — |
| 2025-09-12 | W. Michael Flanagan | Chief Scientific Officer | MIXED | — | — |
| 2025-09-09 | TROY EDWARD WILSON | Director | MIXED | — | — |
| 2025-09-05 | Sarah Boyce | President and CEO | MIXED | — | — |
| 2025-09-05 | Eric Mosbrooker | Chief Commercial Officer | MIXED | — | — |
| 2025-09-02 | Kathleen P. Gallagher | Chief Program Officer | Sell | — | — |
| 2025-08-29 | Sarah Boyce | President and CEO | MIXED | — | — |
| 2025-08-22 | Steven George Hughes | Chief Medical Officer | MIXED | — | — |
| 2025-08-15 | Michael F MacLean | Chief Financial Officer | Sell | — | — |
| 2025-08-15 | Teresa McCarthy | Chief Human Resources Officer | MIXED | — | — |
| 2025-08-15 | Steven George Hughes | Chief Medical Officer | MIXED | — | — |
| 2025-08-08 | ARTHUR A LEVIN | Director | MIXED | — | — |
| 2025-08-08 | Eric Mosbrooker | Chief Commercial Officer | MIXED | — | — |
| 2025-08-08 | Steven George Hughes | Chief Medical Officer | MIXED | — | — |
| 2025-08-08 | TROY EDWARD WILSON | Director | MIXED | — | — |
| 2025-08-05 | John B Moriarty | Chief Legal Officer | Sell | — | — |
| 2025-06-18 | Kathleen P. Gallagher | Chief Program Officer | Sell | — | — |
| 2025-06-12 | Tamar Thompson | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | See Remarks | 131,361 | — |
| — | Chief Medical Officer | 73,097 | — |
| — | Chief Scientific Officer | 52,657 | — |
| — | Chief Strategy Officer | 46,660 | — |
| — | Chief Financial Officer | 43,601 | — |
| — | See Remarks | 35,460 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RNA quote page; the site-wide leaderboard is on the insider transactions hub.